A Look at Where We Came from and Where We Are Going

Cytometry Part A

Volumn 58, Issue 1, 2004, Pages 53-54

  Goolsby, Charles ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BCR ABL PROTEIN; RITUXIMAB;

CANCER CELL; CELL FUNCTION; CELL SUBPOPULATION; CLINICAL LABORATORY; CYTOLOGY; CYTOMETRY; FLOW CYTOMETRY; GENOMICS; HUMAN; MEDICAL LITERATURE; MEDICAL SOCIETY; PATIENT MONITORING; PRIORITY JOURNAL; PROTEOMICS; REVIEW;

EID: 1542619412     PISSN: 15524922     EISSN: None     Source Type: Journal    
DOI: 10.1002/cyto.a.20010     Document Type: Review

References (3)

1. Chow S, Patel H, Hedley DW. Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors. Commun Clin Cytometry 2001;46:72-78.
2. Perez OD, Nolan GP. Simultaneous measurement of multiple active kinase states using polychromatic flow cytometry. Nat Biotechnol 2002;20:155-162.
3. Jacobberger JW, Sramkoski RM, Frisa PS, Ye PP, Gottlieb MA, Hedley DW, Shankey TV, Smith BL, Paniagua M, Goolsby CL. Immunoreactivity of Stat5 phosphorylated on tyrosine on 694 as a cell-based measure of Bcr/Abl kinase activity. Cytometry 2003;54A: 75-88.